Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has completed construction of its new API manufacturing facility for investigational antibody within the premises of Hikari Plant.
Subscribe to our email newsletter
Earlier, Takeda collaborated with its wholly-owned subsidiaries Takeda San Francisco, Millennium Pharmaceuticals, Takeda Bio Development Center and Chemistry, Manufacturing and Controls (CMC) Center to commercialize new drug candidate substances for antibody.
The new plant, located in Hikari City, Yamaguchi Prefecture, Japan, aims to capitalize on the collaboration to research and develop manufacturing processes, and accelerate the production of investigational drug substances.
Takeda Pharma CMC Center general manager Tetsuo Miwa said they are delighted with the completion of the construction of the New Facility that is set to assume a crucial role in the creation of antibody drugs that have potential to meet unmet needs.
"By promoting the development of optimal antibody drugs and strengthening of CMC technical platforms based on our global network, we are determined to commit ourselves to bring superior new medicine to patients as promptly as possible," Miwa said.